Differentiation of clear from non-clear cell renal cell carcinoma using CT washout formula

被引:0
|
作者
Kopp, Ryan P. [1 ,2 ]
Aganovic, Lejla [3 ,4 ]
Palazzi, Kerrin L. [1 ]
Cassidy, Fiona H. [3 ,4 ]
Sakamoto, Kyoko [1 ,2 ]
Derweesh, Ithaar H. [1 ,2 ]
机构
[1] Univ Calif San Diego, Sch Med, Dept Surg, Div Urol, La Jolla, CA 92093 USA
[2] San Diego Vet Adm Med Ctr, Surg Serv, La Jolla, CA USA
[3] Univ Calif San Diego, Sch Med, Dept Radiol, La Jolla, CA 92093 USA
[4] San Diego Vet Adm Med Ctr, Serv Radiol, La Jolla, CA USA
关键词
carcinoma; renal cell; computerized tomography; diagnosis; enhancement; histology; Hounsfield unit; PATHOLOGICAL FEATURES; CORTICAL TUMORS; CORE BIOPSY; MASSES; SUNITINIB; PAPILLARY; EFFICACY; CM;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: To further elucidate potential patterns of contrast enhancement for renal neoplasm subtypes, we investigated utility of contrast washout formula to differentiate renal tumor histology after multiphase computerized tomography (CT). Materials and methods: Single center retrospective cohort study of 163 patients with multiphase CT for renal masses obtained October 2007 to July 2012. Pathology confirmed clear cell (CC-RCC; n = 92), papillary (Pa-RCC; n = 43), chromophobe (Ch-RCC; n = 6), oncocytoma (OC; n = 11), or angiomyolipoma (AML; n = 11) histology. Two radiologists in consensus and blinded to histology recorded tumor size, morphology, and attenuation measurements in Hounsfield Units (HU). Data were analyzed between subgroups based on histology. Enhancement washout of the tumor was calculated by the formula (Mass nephrographic HU-Mass delayed HU)/(Mass nephrographic HU-Mass non-contrast HU) and used to calculate sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Results: Tumor size was largest among CC-RCC (p < 0.001). Homogeneous composition was more common among Pa-RCC and Ch-RCC (p < 0.001). Median washout for Ch-RCC (0.27) was significantly different from that of OC (0.54, p = 0.05). Overall 25 (15.3%) of tumors had washout < 0. Tumors with washout value < 0 were Pa-RCC 24/43 (56%), and Ch-RCC 1/6 (14%). Washout value < 0 had a specificity of 99.2% for Pa-RCC and 100% for non-CC-RCC. Washout value >= 0 had a sensitivity and NPV of 100% for CC-RCC, OC, and AML. Washout value 0 had a specificity of 35.2% and a PPV of 66.7% for CC-RCC. Conclusions: Enhancement washout value < 0 is highly specific for Pa-RCC and non-CC-RCC. Washout value 0 is highly sensitive for CC-RCC, OC, and AML while there was a significant difference in median washout between OC and Ch-RCC. Further prospective investigation is requisite to confirm these findings.
引用
收藏
页码:6790 / 6797
页数:8
相关论文
共 50 条
  • [31] Non-clear cell renal cell carcinoma (nccRCC): A Brazilian experience.
    Yamamura, Rosely
    Rinck, Jose A.
    Fonseca Jesus, Victor Hugo
    Tavares, Monique Celeste
    de Castro Larclprete, Ana Luisa
    Iennaco, Pietro Schettlni
    Freitas, Heleno C.
    Cunha, Isabela Warneck
    Fanelli, Marcello Ferretti
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review
    Sneed, Gregory T.
    Lee, Sukdong
    Brown, Jamie N.
    Hammond, Julia M.
    CLINICAL GENITOURINARY CANCER, 2019, 17 (06) : 419 - 424
  • [33] Clinical outcomes of checkpoint inhibitors in metastatic non-clear cell renal cell carcinoma and clear cell renal cell carcinoma with variant features.
    Chang, Guy vin
    Ellithi, Moataz
    Elnair, Radowan
    Bleeker, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Metastatic non-clear cell renal cell carcinoma: current therapeutic options
    Schrader, Andres J.
    Olbert, Peter J.
    Hegele, Axel
    Varga, Zoltan
    Hofmann, Rainer
    BJU INTERNATIONAL, 2008, 101 (11) : 1343 - 1345
  • [35] The genomic landscape of metastatic non-clear cell renal cell carcinoma.
    Carlo, Maria Isabel
    Khan, Nabeela
    Chen, Yingbei
    Hsieh, James
    Hakimi, A. Ari
    Lee, Chung-Han
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [36] Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
    Koshkin, Vadim S.
    Barata, Pedro C.
    Zhang, Tian
    George, Daniel J.
    Atkins, Michael B.
    Kelly, William J.
    Vogelzang, Nicholas J.
    Pal, Sumanta K.
    Hsu, JoAnn
    Appleman, Leonard J.
    Ornstein, Moshe C.
    Gilligan, Timothy
    Grivas, Petros
    Garcia, Jorge A.
    Rini, Brian I.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [37] Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma
    Shi, Hong-Zhe
    Tian, Jun
    Li, Chang-Ling
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 (04) : 328 - 333
  • [38] Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light
    Albiges, Laurence
    Flippot, Ronan
    Rioux-Leclercq, Nathalie
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (36) : 3624 - +
  • [39] In vitro cellular and molecular effects of oncolytic vaccinia virus in clear and non-clear cell renal cell carcinoma
    Jing, Yuqi
    Guerrero, F. Bustamante
    Merchan, Jaime
    CANCER RESEARCH, 2022, 82 (12)
  • [40] Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
    Lee, Jii Bum
    Park, Hyung Soon
    Park, Sejung
    Lee, Hyo Jin
    Kwon, Kyung A.
    Choi, Young Jin
    Kim, Yu Jung
    Nam, Chung Mo
    Cho, Nam Hoon
    Kang, Beodeul
    Chung, Hyun Cheol
    Rha, Sun Young
    CANCER RESEARCH AND TREATMENT, 2019, 51 (04): : 1578 - 1588